Case report

Unexpected responses to EGFR inhibition in NSCLC

Giulia M. Stella a,*, 1, Claudio Valzina a,1, Michele Zorzet a, Simona Inghilleri a, Adele Valentini b, Roberto Dore b, Sara Colombo c, Francesco Valentino d, Giulio Orlandon e, Patrizia Morbinif

a Department of Molecular Medicine, Laboratory of Biochemistry and Genetics, Pneumology Unit, University and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
b Department of Hemato-oncology, Section of Pathology, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
c Department of Hemato-oncology, Medical Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
d Department of Hemato-oncology, Radiation Therapy, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
e Cardiothoracic Surgery Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
f Department of Molecular Medicine, Laboratory of Biochemistry and Genetics, Pneumology Unit, University and Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy

Article history:
Received 5 June 2015
Accepted 24 June 2015

Keywords:
Cancer genetics
Actionable markers
Targeted therapy

Abstract

The presence of activating mutations of the epidermal growth factor receptor (EGFR)-gene identifies a distinct and clinically relevant molecular subset of non-small-cell lung cancer. It is now well demonstrated that EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are superior to standard chemotherapy in this subset of tumors. Nevertheless, in many cases, responses are not durable and last for 6–12 months due to the occurrence of secondary or acquired resistance. Here we present three cases of EGFR-mutant lung adenocarcinomas (ADC), that showed an unexpected response to anti-EGFR small molecules. The first patient presented a continued 89 month-long response to erlotinib in a tumor occurred after surgery and conventional chemotherapy. In the other cases, subclinically persistent tumor in the lung tissue was documented histologically in lung resections performed after partial response to TKI treatment. The persistence of interstitial and endolymphatic tumor cells after TKI treatment might explain the common observation of tumor relapse after TKI discontinuation, and sustain the decision to continue treatment in responsive patients as in our first case.

© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) identifies a distinct and clinically relevant molecular subset of lung cancer. Activating EGFR somatic mutations have emerged as the most relevant predictor of response to small EGFR tyrosine kinase inhibitors (TKIs) and is now well demonstrated that in patients whose tumors harbor EGFR mutations, EGFR TKIs, gefitinib and erlotinib, are superior to chemotherapy in terms of response rates, progression free survival, quality of life and toxicity profile. Nevertheless in many cases responses are not durable, as more often TKI stabilize the disease for 6–12 months followed by the occurrence of secondary or acquired resistance [1].

Here we present three EGFR-mutant lung adenocarcinoma (ADC) patients, worth to be reported due to their unusual response to anti-EGFR small molecules. Clinical and molecular details are reported in Tables 1 and 2. The first is a 61-year-old Caucasian, never smoker female who in 2005 underwent left superior lung lobectomy for an early stage (T1N0M0 [2]) ADC. Mutational analysis performed on the resected tumor tissue revealed a deletion affecting exon 19 of the EGFR gene, without gene amplification, whereas no mutations were found in KRAS exon 2, PIK3CA exons 9–20, BRAF exon 15 coding sequences; neither HER2 amplification nor mutation were documented. Molecular analyses were performed as previously described [3]. Based on disease stage adjuvant therapy was not administered. Regular clinical and imaging follow up in 2006 showed at CT scan a mediastinal lymphadenopathy suggestive for disease progression. Subsequent CT-guided biopsy confirmed the diagnosis of lymphnode metastasis of lung ADC. Metastatic cells carried the same genetic profile of the primary tumor. Subsequent analysis demonstrated the absence of EML4/ALK...
translocation. A platinum gemcitabine doublet was thus started. CT scan after three cycles showed disease progression with the appearance of a small nodule in the left lung and the coexistence of pathological mediastinal lymphnodes. Based on the mutational profile of both tumor and secondary lesion, erlotinib 150 mg/day was started at the beginning of 2007. The first CT control after three months of treatment revealed a slight reduction of malignant lesion size. A further reduction was documented after 6 months of therapy, in September 2007. Quite unexpectedly, the patient is since then showing a prolonged response with persistent disease control after 89 months of continued therapy, in absence of significant toxicities (mild anemia). Related CT scan images are reported in Fig. 1.

A 65-year-old former smoker Caucasian woman was diagnosed in 2012 with an ADC of left inferior lobe, associated with mediastinal lymphoadenopathy and pleural secondary lesions. Based on the detection of the L858R EGFR mutation, therapy with gefitinib was started. CT scan after six months of therapy showed a partial response with shrinkage of the tumor primary lesion, complete resolution of the pleural effusion, and stability of hilar nodes. After a multidisciplinary evaluation, the patient underwent surgical lobectomy. The histological examination of the surgical sample showed a fibroelastic area corresponding to the lesion documented on CT, associated with diffuse interstitial and lymphatic spread of minute tumor aggregates in subpleural, perivascular and peribronchial areas. No evidence of interstitial lung disease was documented. Treatment with gefitinib was thus resumed and continued until now (months) in absence of clinically detectable disease recurrence. The last patient was a 49-year-old former smoker Caucasian, who was diagnosed in 2012 with stage IV lung ADC, metastatic to the brain (single lesion). The tumor carried a deletion of the exon 19 of the EGFR coding sequence. Whole brain radiotherapy (30 Gy) was started in association to gefitinib. CT scan after six months of therapy demonstrated a single lung nodule, in absence of brain and abdominal disease. After a multidisciplinary evaluation, lung tumor was resected. On histological examination, focal fibroelasticosis was identified, and minute tumor aggregates were observed in the perivascular and peribronchial interstitium and lymphatics with a micronodular appearance. Interstitial lung disease was not observed. Based on these data, gefitinib was continued until disease progression 8 months after surgery.

Table 1
Clinical data on the three patients described.

| ID | Gender | Age at diagnosis (yrs) | Smoking habit (pack/yr) | TNM at diagnosis | PFS (months) | OS (months) |
|----|--------|------------------------|-------------------------|------------------|--------------|-------------|
| 1  | F      | 61                     | never smoker (<50)      | T1N0M0           | 89           | 114         |
| 2  | F      | 65                     | past smoker (<30)       | T4N1M0           | 31           | 31          |
| 3  | M      | 49                     | past smoker (>70)       | T2N1M1           | 14           | 16          |

Notably, in both case 2 and 3 known molecular mechanisms of genetic resistance to EGFR inhibitors were tested on biopitic samples at diagnosis and on subsequent available surgical specimens: no EGFR T790M mutation were documented and tumors DNA harbored a wild type KRAS and MET coding sequences, no EGFR and MET gene amplifications were found as well. Case 2 and 3 historical and CT scan images are presented in Fig. 1.

The EGFR TKIs, gefitinib and erlotinib, act as reversible competitive inhibitors of the tyrosine kinase domain of EGFR that bind to its adenosine-5'-triphosphate-binding site. Somatic EGFR activating mutations in NSCLC have been associated with dramatic tumor responses and favorable clinical outcomes with these molecules. However, most patients who initially respond to gefitinib and erlotinib eventually become resistant and experience disease progression. We present here the case of a really continued response – nearly a complete disease remission – induced by erlotinib in an advanced EGFR-mutant lung ADC, which recurred after surgery and the failure of conventional chemotherapy. This is to our knowledge among the most impressive documented responses to EGFR TKIs in NSCLC, deserving some considerations. A major point concerns the therapeutic context in which such a prolonged treatment must be placed. It is known that maintenance therapy with erlotinib or gefitinib produces a significant increase of progression-free survival (PFS) and overall survival (OS) in NSCLC patients [4]. Nevertheless, it is conceivable that the persistently responsive phenotype observed here might be driven by a tumor and/or host genetic asset which cooperates in sustaining addiction [5] to the small TKI. In order to verify this hypothesis we checked the molecular profile of a panel of genes involved in the EGFR signaling pathway, which are known to play a major role in lung malignant transformation, and no mutation was documented. Altered expression of the ERCC1 gene was not identified as well (data not shown). Another relevant issue is related to if and when TKI should be discontinued in responsive patients, mainly when, after prolonged treatment, imaging data continue to be negative for disease evidence. In other words, in such unexpected setting (as in the first case reported) is it allowed to stop anti EGFR therapy? In order to answer to this question, we present two other cases which are not relevant for the duration of response to small EGFR inhibitors, but really because for both of them large surgical specimens of tumors exposed to TKIs are available for histo-pathological

Table 2
Molecular profile of the analyzed cases. For case 2 and 3, in green data red data obtained on biopsy at diagnosis and confirmed on subsequent surgical specimens; in blue data evaluated in only surgical specimen to analyze the status of transducers involved in acquired resistance to anti EGFR agents.

| ID | Case | EGFR mutation | HER2 amplification | KRAS mutation | PIK3CA mutation | BRAF mutation | MET amplification | EML/ALK translocation |
|----|------|---------------|-------------------|---------------|-----------------|--------------|------------------|---------------------|
| 1  |      | del ex 19     | euploid           | wt            | wt              | wt           | wt                | no                  |
| 2  |      | L858R         | euploid           | wt            | wt              | wt           | wt                | euploid             |
| 3  |      | del ex 19     | euploid           | wt            | wt              | wt           | wt                | euploid             |
analysis. Thus, the other two cases reported provide helpful insights on how TKIs behave at the microscopic level. Indeed, while it is well documented that genetic variation in EGFR pathway genes may confer susceptibility to interstitial lung diseases (ILDs) [6,7] very few morphological data are available on the tumor histological response to small EGFR inhibitors. We observed in both cases the disappearance of the initial tumor mass, however associated with the diffuse persistence of tumor cell aggregates in the lymphatic vessel. This observation has so far not been reported in the few studies analyzing post-TKI lung resections [8–10], most of which focused on early tumor response to neoadjuvant treatment. The subclinical persistence of interstitial and endolymphatic tumor cells after prolonged TKI treatment might explain the common observation of tumor relapse after TKI discontinuation, and sustain the decision to continue treatment in responsive patients as we did in our first case. Clearly, further investigations are required to define the molecular profile of these persistently responsive patients and to distinguish them from the vast majority of those that develop acquired resistance.

Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

References

[1] W. Pao, J. Chmielecki, Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer, Nat. Rev. Cancer. 10 (11) (2010 Nov) 760–774.
[2] P. Therasse, S.G. Arbuck, E.A. Eisenhauer, et al., New guidelines to evaluate the response to treatment in solid tumors, J. Natl. Cancer Inst. 92 (2000) 205–216.
[3] G.M. Stella, S. Benvenuti, D. Gramaglia, et al., MET mutations in cancers of unknown primary origin (CUPs), Hum. Mutat. 32 (1) (2011 Jan) 44–50.
[4] Chen X, Liu Y, Roe Od, et al. Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. PloS One 8(3):e59314
[5] I.B. Weinstein, Oncogenic addiction- the Achilles heel of cancer, Science 297 (5578) (2002) 63–64.
[6] W.X. Qi, Y.J. Sun, Z. Shen, et al., Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials, J. Chemother. 27 (1) (2015 Feb) 40–51.
[7] C. Li, R. Wei, Y.L. Jones-Hall, et al., Epidermal growth factor receptor (EGFR) pathway genes and interstitial lung disease: an association study, Sci. Rep. 4 (2014) 4893.
[8] A. Lopez-Gonzales, E. Almagro, C. sala, et al., Use of tyrosine kinase inhibitor as neoadjuvant therapy for non-small cell lung cancer: a case report, Resp. Med. Case Rep. 9 (2013) 8–10.
[9] H. Lara-Guerra, C.T. Chung, M.P. Joerg-Schwock, et al., Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer, Lung Cancer 76 (2012) 235–241.
[10] E.E. Schaeke, I. Kappers, E. Codrington, et al., Tumor responses and toxicity of neoadjuvant erlotinib in patients with early stage non-small-cell lung cancer, J. Clin. Oncol. 30 (2012) 2731–2738.